458.49
price down icon0.29%   -1.32
after-market 시간 외 거래: 456.46 -2.03 -0.44%
loading
전일 마감가:
$459.81
열려 있는:
$459.81
하루 거래량:
800.28K
Relative Volume:
0.53
시가총액:
$117.74B
수익:
$11.10B
순이익/손실:
$-988.90M
주가수익비율:
-116.96
EPS:
-3.92
순현금흐름:
$-1.26B
1주 성능:
-2.93%
1개월 성능:
+4.00%
6개월 성능:
+7.15%
1년 성능:
-6.73%
1일 변동 폭
Value
$456.83
$462.31
1주일 범위
Value
$456.83
$475.29
52주 변동 폭
Value
$377.85
$519.88

버텍스 파마슈티컬 Stock (VRTX) Company Profile

Name
명칭
Vertex Pharmaceuticals Inc
Name
전화
(617) 341-6393
Name
주소
50 NORTHERN AVENUE, BOSTON, MA
Name
직원
6,100
Name
트위터
@VertexPharma
Name
다음 수익 날짜
2025-02-10
Name
최신 SEC 제출 서류
Name
VRTX's Discussions on Twitter

VRTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-07 다운그레이드 Wolfe Research Outperform → Peer Perform
2025-05-06 다운그레이드 Leerink Partners Outperform → Market Perform
2025-04-22 재개 Cantor Fitzgerald Overweight
2025-02-12 업그레이드 Canaccord Genuity Sell → Hold
2025-02-11 업그레이드 Canaccord Genuity Sell → Hold
2025-01-30 다운그레이드 Wells Fargo Overweight → Equal Weight
2024-12-20 재확인 H.C. Wainwright Buy
2024-12-19 다운그레이드 Oppenheimer Outperform → Perform
2024-12-09 업그레이드 Jefferies Hold → Buy
2024-11-14 개시 Citigroup Buy
2024-10-16 개시 Scotiabank Sector Perform
2024-10-10 재개 Raymond James Mkt Perform
2024-08-05 다운그레이드 Barclays Overweight → Equal Weight
2024-06-27 개시 Redburn Atlantic Buy
2024-04-11 업그레이드 Evercore ISI In-line → Outperform
2024-02-15 개시 Wolfe Research Outperform
2024-02-06 다운그레이드 Evercore ISI Outperform → In-line
2024-02-02 다운그레이드 Bernstein Outperform → Mkt Perform
2024-01-31 다운그레이드 Maxim Group Buy → Hold
2024-01-31 다운그레이드 Robert W. Baird Neutral → Underperform
2024-01-24 다운그레이드 Canaccord Genuity Hold → Sell
2023-12-14 재확인 RBC Capital Mkts Sector Perform
2023-05-30 개시 William Blair Outperform
2023-05-04 재개 Piper Sandler Overweight
2023-03-21 개시 Bernstein Outperform
2023-01-18 개시 Canaccord Genuity Hold
2023-01-17 업그레이드 SVB Leerink Mkt Perform → Outperform
2022-12-19 다운그레이드 Jefferies Buy → Hold
2022-07-13 개시 Cantor Fitzgerald Overweight
2022-06-01 업그레이드 Maxim Group Hold → Buy
2022-05-23 개시 SVB Leerink Mkt Perform
2022-05-06 다운그레이드 Robert W. Baird Outperform → Neutral
2022-05-03 업그레이드 Morgan Stanley Underweight → Equal-Weight
2022-02-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2022-01-27 재확인 JP Morgan Overweight
2022-01-27 재확인 Morgan Stanley Underweight
2022-01-27 재확인 RBC Capital Mkts Outperform
2022-01-27 재확인 Stifel Hold
2022-01-27 재확인 Wolfe Research Outperform
2022-01-20 업그레이드 BMO Capital Markets Market Perform → Outperform
2021-12-09 개시 Wells Fargo Overweight
2021-11-19 개시 BMO Capital Markets Market Perform
2021-11-19 다운그레이드 Piper Sandler Overweight → Neutral
2021-09-09 다운그레이드 Stifel Buy → Hold
2021-09-07 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2021-07-20 다운그레이드 SVB Leerink Mkt Perform → Underperform
2021-07-19 재개 Wolfe Research Outperform
2021-07-01 개시 Raymond James Mkt Perform
2021-06-11 다운그레이드 Daiwa Securities Outperform → Neutral
2021-02-23 업그레이드 Robert W. Baird Neutral → Outperform
2021-02-02 재확인 H.C. Wainwright Buy
2020-12-30 개시 Daiwa Securities Outperform
2020-11-30 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2020-11-20 개시 Bernstein Outperform
2020-10-28 개시 UBS Buy
2020-07-31 재확인 H.C. Wainwright Buy
2020-07-08 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-04-30 재확인 H.C. Wainwright Buy
2020-04-28 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2020-03-04 개시 Barclays Overweight
2020-01-31 다운그레이드 Robert W. Baird Outperform → Neutral
2019-11-19 업그레이드 Guggenheim Neutral → Buy
2019-11-12 개시 SunTrust Buy
2019-10-17 재개 BofA/Merrill Buy
2019-09-03 업그레이드 Goldman Neutral → Buy
2019-08-01 다운그레이드 Needham Buy → Hold
2019-05-23 재개 Citigroup Buy
2019-05-21 개시 Credit Suisse Outperform
2019-04-12 개시 Evercore ISI In-line
2019-03-26 업그레이드 William Blair Mkt Perform → Outperform
2019-03-19 다운그레이드 SVB Leerink Outperform → Mkt Perform
2019-02-06 다운그레이드 Maxim Group Buy → Hold
모두보기

버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스

pulisher
10:01 AM

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

10:01 AM
pulisher
12:07 PM

3 Monster Stocks in the Making to Buy Right Now - The Motley Fool

12:07 PM
pulisher
Jul 20, 2025

Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Is Vertex Pharmaceuticals Incorporated a good long term investmentMarket-leading growth rates - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Vertex Pharmaceuticals Incorporated stock priceFree Stock Selection - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Vertex Pharmaceuticals Incorporated stockAccelerated wealth expansion - Jammu Links News

Jul 19, 2025
pulisher
Jul 18, 2025

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative

Jul 16, 2025
pulisher
Jul 16, 2025

Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Jul 16, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug - BioPharma Dive

Jul 15, 2025
pulisher
Jul 15, 2025

Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma - Barchart.com

Jul 15, 2025
pulisher
Jul 15, 2025

EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures NHS deal for once-daily cystic fibrosis therapy - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE - PMLiVE

Jul 15, 2025
pulisher
Jul 15, 2025

NICE backs Vertex's cystic fibrosis triple combo Alyftrek - FirstWord Pharma

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Receives a Buy from J.P. Morgan - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

New cystic fibrosis triple from Vertex backed for NHS use - pharmaphorum

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals and NHS England Reach Agreement to Provide Alyftrek for Cystic Fibrosis Treatment - geneonline.com

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain - BioSpace

Jul 15, 2025
pulisher
Jul 14, 2025

Vertex Pharmaceuticals' ALYFTREK® Approval: A Catalyst for EU Dominance and Revenue Growth? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX - Business Wire

Jul 14, 2025
pulisher
Jul 13, 2025

Vertex Pharmaceuticals: A Steady Hand in a Volatile Market - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Vertex Pharmaceuticals Leads Biotech Stocks with 16%+ YTD Increase - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Why Vertex Pharmaceuticals Continues To Outperfrom (NASDAQ:VRTX) - Seeking Alpha

Jul 13, 2025
pulisher
Jul 11, 2025

Small Fiber Neuropathy Market Growth Projections 2023-2032: DelveInsight Analysis | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma, Glenmark Pharma, Regency - Barchart.com

Jul 11, 2025
pulisher
Jul 10, 2025

Regulatory tracker: Vertex, NHS England reach reimbursement deal for CF drug Alyftrek - Fierce Pharma

Jul 10, 2025
pulisher
Jul 09, 2025

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch (NASDAQ:VRTX) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval - PMLiVE

Jul 09, 2025
pulisher
Jul 08, 2025

Vertex Pharmaceuticals Q2 2025 Earnings: A Catalyst for Dominance in Rare Disease Therapeutics - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Vertex to Announce Second Quarter 2025 Financial Results on August 4th - Business Wire

Jul 08, 2025
pulisher
Jul 08, 2025

Cystic Fibrosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma - Barchart.com

Jul 08, 2025
pulisher
Jul 08, 2025

RBC Capital Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 08, 2025

Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)? - Insider Monkey

Jul 08, 2025
pulisher
Jul 08, 2025

FDA Approves Suzetrigine by Vertex Pharmaceuticals for Acute Pain Relief in Adults - geneonline.com

Jul 08, 2025
pulisher
Jul 08, 2025

Vertex Pharmaceuticals to Announce Q2 2025 Earnings on August 4th - AInvest

Jul 08, 2025
pulisher
Jul 07, 2025

China Universal Asset Management Co. Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat

Jul 07, 2025
pulisher
Jul 03, 2025

Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY - Yahoo Finance

Jul 03, 2025
pulisher
Jul 02, 2025

VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 02, 2025
pulisher
Jul 02, 2025

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek - Nasdaq

Jul 02, 2025
pulisher
Jul 01, 2025

Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU - Stocktwits

Jul 01, 2025
pulisher
Jul 01, 2025

, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire

Jul 01, 2025
pulisher
Jun 30, 2025

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock? - Yahoo Finance

Jun 30, 2025

버텍스 파마슈티컬 (VRTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$545.53
price up icon 0.55%
$320.52
price down icon 0.00%
$566.14
price up icon 0.27%
biotechnology ONC
$291.93
price down icon 0.89%
$108.91
price down icon 1.01%
자본화:     |  볼륨(24시간):